pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-1208 |
Genomic Coordinates | chr8: 128150116 - 128150188 |
Synonyms | MIRN1208, hsa-mir-1208, MIR1208 |
Description | Homo sapiens miR-1208 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-1208 | |||||||||||||||||||||||||||
Sequence | 12| UCACUGUUCAGACAGGCGGA |31 | |||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||
Experiments | Northern | |||||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | OPHN1 | ||||||||||||||||||||
Synonyms | ARHGAP41, MRX60, OPN1 | ||||||||||||||||||||
Description | oligophrenin 1 | ||||||||||||||||||||
Transcript | NM_002547 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on OPHN1 | |||||||||||||||||||||
3'UTR of OPHN1 (miRNA target sites are highlighted) |
>OPHN1|NM_002547|3'UTR 1 GGCTACAGGTTTTAAAAGCCTTGGCCTCAGAGGACCCTTTCCAGGTTCTGAAAGAGTCTTTCTTCTTCAAACCTTTGTGT 81 GCGGAGTCATTTTGTGTTGAAGAGCAGCTCCTTCCTAGCCTTGCACTTTCAGACTCTCTCTGGGAGGCCATAAAATAAGG 161 AGCATATGTCCTAGACAGGTGTTTATATCTCCTTTGTATTCTGTCTTCATCCCCTCAGAAGGTCTGTTTTGAGTTCCTAT 241 AACACTGTGAAGAGCTGGACTCCCTCAAGCCAGACTCTGCCAAAACCAAGATATCCACTTACCTGAGTTGAAGAGGGGAG 321 CTCAGTTTTCAACTCTTCCCTGAACTTCCTGCTTCCTCAGAGGGCCATTGAACTCTGAGAGATTTGGGGCTAAAGACTGA 401 TCTCAGGGGTCTTACCTTGAACTGAAGGCCACTTGAGTTGGGGCCATTGCTTACCTTGGTTGGAAGGGAATAGAAATGTT 481 TGCTGAACATTGGAGAATCTCAACATGTCTCCTACTGAGGATATGGACACTGGTGCCATGTCAGCGCTCTGGTGCTGCAG 561 TATGTTGCCAAGAGCCCGTCTGCTCCTGCGAGGCTATGAGTGGGATGAGTGATGCCCCCACAGCACCTCCATGTGGACTT 641 AGGAAGGTGGCCTTCCTGCTGTTACATGCAGCCACTTAGGACAAATCTGCAAAGCATGTTTTGCATGTAAAAGCCTAGGT 721 CTATTTGGATTATTCTTTCTCCTTTTTTTTGACAGCTTCCTGTCAAGCAATCAAGAAACAAACAAAAGCTGAACACATTT 801 CTTTTTAAAAAAAGGAGACTGTGTTTGGTCCTGTAGGAGTTCTATTTTGGGGTCAAATGCTAGAAAAATTGTTAAGGTGG 881 ATTGAGGCCAGGCAGCTGTCACTGCTGCTTCATGTTTGCCTTCTGCACATAAACTCTTTTATCTCCTGAAAAAAGCAGTT 961 CTTAACCCAGTGTCCATGGACTCAGAAACTCCATGATGCCCCTGAGATGGTATGCACAATTCCATGACAATATGCCCTTT 1041 CTGGGGAGATAGTCCATAATGTTCTGCTAAATTTCAAATGGGCTCGTGACCCAAAAAAGTCAAGAACCACAGCACTTGAG 1121 TAAAATACTCTTTTTACAATCCATATAAGCCCTTGATTGGAAGGGCTTTTCAAAATCATTTAGTCTAACAACTGCCCAGT 1201 TTCCAGTCGGGGGAACTGAGGCAGAGCAAGGTAGTGATCACACCAGTACAAGATCTCAGGTCCCAGGCTCCTATGCAAGT 1281 TTTTTTTCCCCATTATATCACACTTATCTAGCAAGGGACCTTGTGGTTTGTGGCTTTAGTGGCCATCATTTCTGGGGGTT 1361 GGCTTTTACCCTTTTTCTTGAATATTTGCCACCAAGTGAAAAATGTTAGGACATAAACCCTTGCCAGGTCCCTTTCATTT 1441 GCTATCTCTATTATTGGAAAGGACCTAAAAATTGGTGTAATGGGGCAGAAATCTGAGGAATGGACATTTCTAATTCCTGT 1521 TTGTTGAAGGGAAGTTGCTGGAAAGAGCATCAGTACTTGTTTCTATGCAGATGCCTGGGCCGTAGCTTGTCTGTAGCGTC 1601 TGTATAATTATAATGTTGCCCAGTGTGAGGGAAAGAGCTTTCCTACTTGCACTCTTCTACCAAGGCCCTGTTAGTGCACT 1681 GATTATAGTACTGACAGATAAACCTAGATAAAGAGATAGAGAGTGAGTACATGCACACTCATGTGCAAACCCACTCAGAG 1761 ATGCATTTGGAACAGTGCTACTGAAAGGCAGTAGTCATTTTCAAGACTGAATTCCAAACATGGTTTATTGGTGAGTTAGG 1841 AACATGTAAGGCCAAGTACACTGAGAGCCTTTTTGAAAGTAATTGAGTGGAAACTTGATGCCATTCTAAATCAAGGCATA 1921 TCCAGGTGGCCCGGTTGAACTCACTCCACTGTACCCAGTCTCAAAGGCCAGGTTGCTAAGAAACCAGGAGTAAAAGAGTC 2001 AAGTGACCATCATTTCACCTGCTGCTTGCCCCCAATAGTAGTCTCTGTGAGGCCTTACTGACCTCACCTAGGAAGTGATT 2081 TTTGAGCCCTTGTTTCAGGGCTGTGGCCTCCCTGCTCTATCCTGAATAAAGCAGACAGGTGTGCAGATTTTGGCCATGAA 2161 AGCATGGCTAATAGGGCCACAGTCCCTTTAAAGAAACATGGTTTGACTCTGGTTTTCTTGGGGGAAAATACCACAATCAC 2241 CGATGCAAACATTGGAAGATTATTGAGAGCCCTAGAAAGCTGCTGTGATCCCAGTAGAAAATATGTCCCAGAAATGTCAT 2321 GAGATTGCTGTGTGTTGCCTGGGACACAGATCAAGGGCCTATCTTGGAGAGCTGGGGACCAGCAGTCTGCCTGGAGGCCA 2401 GGGAGCAGTGGCTGAGTAGCTCTGCCTTTGCTCTGGTCTATACCTTAAGAATGCCAAAGAATGAATTTCAACGCCTGCCT 2481 TTGGCACTCTGACTTAAAGTGCAAAAAGCTTCTGTGGCGAGGCATGCTATCATGGAATGAGACTGGCTTGCCCTAGGCTT 2561 AATGGATGGGCAGTCATTTTGCAGAGGCTATGGGAAGAGGGTGATAATAGAAGAGTGGCAGCTATAGGAAATTATCAACA 2641 TACCTTGGCCAGCAAGTTAGAGAATCTGGCAATGGATGAACTGAAAGTGATGAACTGGCAGGGATAACAAAGAACCTAAC 2721 ATTTATTAAGCACGTATTTATTAACTGCTCAGTGTTTCATATTCATGCAAGTATTCTCATTTTACAGAGAAAGAAATTAT 2801 GGCCCAGGGGGCTAAAGTAAACAACTCAAGGGCACATAGAAAGTAAATAAAAGGACTGTGATTTGAATCCAGGCCACTCT 2881 TAGCCCATGCTGTTTTCCCTTTGCCACACTGTGGTAGGTGTTTGAACAGAGGCCACATTACTAGAGTTGGCATGACTCTT 2961 GACTCTTGCCTGCCTAACAAAATATTGAAAGGCAAACATTTGAAGGAGGGAGGGGGTGCAGGTTCAGTTTATATGGAAAT 3041 GCAAACTGGGCTGGAAGATATTCCTGAGTTAGGCTTTCTCTTCATATTCAGCTTGCACATTTGGTAATGTTTTTAAGATG 3121 ATCATCTAATTTTATTTTGTGAAGTGAAGGATTTGTGTTTTAGTTGGCAGTTGTTAAGTCCTTGGCTTGCCATTTTTCAA 3201 AAAGTAAAAAGGTCCTCACAGGTGTCTCCATACTTCGCCAAGGTTGTAGCATGGGCAGTTTCAGTTTCAGCCTAAGAGAC 3281 TGGTGACATCCACAAATGCAGTTTTAGAAGCAGAAAAGGTCTTGGTGCCTCTGCAGTACTTGATGTATTGGGGTCAAATC 3361 TCTACAAATTTTTCTGTGGTGATAGCAAAATCAAGAGATGGCTTACAAAAAGAAATATTGAATTTTTATTTTTGAAGTTT 3441 TTGTTTTTTAAAAGGTTGGGGGTGTTCAGCCACTGAGGGACAAAACTTAGCATCTAATTTCAATTATAGTGTCATGCAGA 3521 GTATTTCTAAAGTAATTGGTTATCATGGGAAAGTATTCTCTTTTCAAGAAGTTCTTTGATTCTGTAATAACTAGAACAAA 3601 TAAAGTAGTAAAAGAAGAAATAGTTCTGTGACTAGGAAAAAATTGCTTTTGAGAGAACATAGATCAATTATACTACTTCT 3681 AAGGTAGCTGCAGATAAGTGGCCTTGACACATTACAAGCCTGGAAAAAAACATCAGAAATAATAAAAAATTTCAGAGAGA 3761 ATCAAGATACCTTTTTTTTTCTTTTTTTTTTCTTTTTTTTATTATACTCTAAGTTTTAGGGTACATGTGCACATTGTGCA 3841 GGTTAGTTACATATGTATACATGTGCCATGCTGGTGCGCTGCACCCACTAATGTGTCATCTAGCATTAGGTATATCTCCC 3921 AGTGCTATCCCTCCCCCCTCCCCCGACCCCACCACAGTCCCCAGAGTGTGATATTCCCCTTCCTGTGTCCATGTGATCTC 4001 ATTGTTCAATTCCCACCTATGAGTGAGAATATGCGGTGTTTGGTTTTTTGTTCTTGCGATAGTTTACTGAGAATGATGGT 4081 TTCCAATTTCATCCATGTCCCTACAAAGGATATGAACTCATCATTTTTTATGGCTGCATAGTATTCCATGGTGTATATGT 4161 GCCACATTTTCTTAATCCAGTCTATCATTGTTGGACATTTGGGTTGGTTCCAAGTCTTTGCTATTGTGAATAGTGCCGCA 4241 ATAAACATACGTGTGCATGTGTCTTTATAGCAGCATGATTTATACTCATTTGGGTATATACCCAGTAATGGGATGGCTGG 4321 GTCAAATGGTATTTCTAGTTCTAGATCCCTGAGGAATCGCCACACTGACTTCCACAATGGTTGAACTAGTTTACAGTCCA 4401 ACCAACAGTGTAAAAGTGTTCCTATTTCTCCGCATCCTCTCCAGCACCTGTTGTTTCCTGACTTTTTAATGATTGCCATT 4481 CTAACTGGTGTGAGATGATATCTCATAGTGGTTTTGATTTGCATTTCTCTGATGGCCAGTGATGATGAGCATTTCTTCAT 4561 GTGTTTTTTGGCTGCATAAATGTCTTCTTTTGAGAAGTGTCTGTTCATGTCCTTCGCGAAGGACAAGATACCTTAAAGAT 4641 AAGTTTTCGATAAAGAAAAGCCTTCATTTTCCTGGGGGAAATGAAGCACTTGATGCCAAGGACATTAGTAGAGGGCTAGA 4721 AAGATTGCCTGTGTGAAAGACATATGCTATATCCAAATAATAAAACAAACGAGATCCTGGGGCTCATTCATGTGACTTTC 4801 AATAAAGTATGTAGACTGTCTAATATAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545213. RNA binding protein: AGO2. Condition:Control
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
CLIP-seq Support 1 for dataset GSM4903829 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Human neurons / CTLTD_shCTL_a |
Location of target site | NM_002547 | 3UTR | CAACAGUGUAAAAGUGUUCCUAUUUCUCCGCAUCCUCUCCAGCACCUGUUGUUUCCUGACUUUUUAAUGAUUGCCAUUCUAACUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161238 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM4903830 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Human neurons / CTLTD_shCTL_b |
Location of target site | NM_002547 | 3UTR | ACCAACAGUGUAAAAGUGUUCCUAUUUCUCCGCAUCCUCUCCAGCACCUGUUGUUUCCUGACUUUUUAAUGAUUGCCAUUCUAACUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161238 |
CLIP-seq Viewer | Link |
CLIP-seq Support 3 for dataset GSM4903831 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Human neurons / 124TD_shELAVL3_a |
Location of target site | NM_002547 | 3UTR | ACCAACAGUGUAAAAGUGUUCCUAUUUCUCCGCAUCCUCUCCAGCACCUGUUGUUUCCUGACUUUUUAAUGAUUGCCAUUCUAACUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161238 |
CLIP-seq Viewer | Link |
CLIP-seq Support 4 for dataset GSM4903832 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Human neurons / 124TD_shELAVL3_b |
Location of target site | NM_002547 | 3UTR | CAACAGUGUAAAAGUGUUCCUAUUUCUCCGCAUCCUCUCCAGCACCUGUUGUUUCCUGACUUUUUAAUGAUUGCCAUUCUAACUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161238 |
CLIP-seq Viewer | Link |
CLIP-seq Support 5 for dataset GSM4903833 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / CTL_TD_21_a |
Location of target site | NM_002547 | 3UTR | CAAAUGGUAUUUCUAGUUCUAGAUCCCUGAGGAAUCGCCACACUGACUUCCACAAUGGUUGAACUAGUUUACAGUCCAACCAACAGUGUAAAAGUGUUCCUAUUUCUCCGCAUCCUCUCCAGCACCUGUUGUUUCCUGACUUUUUAAUGAUUGCCAUUCUAACUGGUGUGAGAUGAUAUCUCAUAGUGGUUUUGAUUUGCAUUUCUCUGAUGGCCAGUGAUGAUGAGCAUUUCUUCAUGUGUUUUUUGGCUGCAUAAAUGUCUUCUUUUGAGAA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 6 for dataset GSM4903834 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / CTL_TD_21_b |
Location of target site | NM_002547 | 3UTR | CUUCCACAAUGGUUGAACUAGUUUACAGUCCAACCAACAGUGUAAAAGUGUUCCUAUUUCUCCGCAUCCUCUCCAGCACCUGUUGUUUCCUGACUUUUUAAUGAUUGCCAUUCUAACUGGUGUGAGAUGAUAUCUCAUAGUGGUUUUGAUUUGCAUUUCUCUGAUGGCCAGUGAUGAUGAGCAUUUCUUCAUGUGUUUUUUGGCUGCAUAAAUGUCUUCUUUUGAGAA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 7 for dataset GSM4903835 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / CTL_TD_21_c |
Location of target site | NM_002547 | 3UTR | UGACUUCCACAAUGGUUGAACUAGUUUACAGUCCAACCAACAGUGUAAAAGUGUUCCUAUUUCUCCGCAUCCUCUCCAGCACCUGUUGUUUCCUGACUUUUUAAUGAUUGCCAUUCUAACUGGUGUGAGAUGAUAUCUCAUAGUGGUUUUGAUUUGCAUUUCUCUGAUGGCCAGUGAUGAUGAGCAUUUCUUCAUGUGUUUUUUGGCUGCAUAAAUGUCUUCUUUUGAGAA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 8 for dataset GSM4903836 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / 124_TD_21_a |
Location of target site | NM_002547 | 3UTR | CUUCCACAAUGGUUGAACUAGUUUACAGUCCAACCAACAGUGUAAAAGUGUUCCUAUUUCUCCGCAUCCUCUCCAGCACCUGUUGUUUCCUGACUUUUUAAUGAUUGCCAUUCUAACUGGUGUGAGAUGAUAUCUCAUAGUGGUUUUGAUUUGCAUUUCUCUGAUGGCCAGUGAUGAUGAGCAUUUCUUCAUGUGUUUUUUGGCUGCAUAAAUGUCUUCUUUUGAGAA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 9 for dataset GSM4903837 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / 124_TD_21_b |
Location of target site | NM_002547 | 3UTR | CUGACUUCCACAAUGGUUGAACUAGUUUACAGUCCAACCAACAGUGUAAAAGUGUUCCUAUUUCUCCGCAUCCUCUCCAGCACCUGUUGUUUCCUGACUUUUUAAUGAUUGCCAUUCUAACUGGUGUGAGAUGAUAUCUCAUAGUGGUUUUGAUUUGCAUUUCUCUGAUGGCCAGUGAUGAUGAGCAUUUCUUCAUGUGUUUUUUGGCUGCAUAAAUGUCUUCUUUUGAGAA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 10 for dataset GSM4903838 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / 124_TD_21_c |
Location of target site | NM_002547 | 3UTR | CUCAUUUGGGUAUAUACCCAGUAAUGGGAUGGCUGGGUCAAAUGGUAUUUCUAGUUCUAGAUCCCUGAGGAAUCGCCACACUGACUUCCACAAUGGUUGAACUAGUUUACAGUCCAACCAACAGUGUAAAAGUGUUCCUAUUUCUCCGCAUCCUCUCCAGCACCUGUUGUUUCCUGACUUUUUAAUGAUUGCCAUUCUAACUGGUGUGAGAUGAUAUCUCAUAGUGGUUUUGAUUUGCAUUUCUCUGAUGGCCAGUGAUGAUGAGCAUUUCUUCAUGUGUUUUUUGGCUGCAUAAAUGUCUUCUUUUGAGAA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 11 for dataset GSM545213 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / Control |
Location of target site | ENST00000355520.5 | 3UTR | UUUACAGUCCAACCA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
55 hsa-miR-1208 Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT076103 | ADORA2B | adenosine A2b receptor | 2 | 2 | ||||||||
MIRT447464 | OSMR | oncostatin M receptor | 2 | 2 | ||||||||
MIRT448145 | ESF1 | ESF1 nucleolar pre-rRNA processing protein homolog | 2 | 2 | ||||||||
MIRT463639 | YY1 | YY1 transcription factor | 2 | 4 | ||||||||
MIRT465065 | TSR1 | TSR1, ribosome maturation factor | 2 | 2 | ||||||||
MIRT468464 | SET | SET nuclear proto-oncogene | 2 | 4 | ||||||||
MIRT480171 | CALM3 | calmodulin 3 | 2 | 2 | ||||||||
MIRT481495 | ARL6IP1 | ADP ribosylation factor like GTPase 6 interacting protein 1 | 2 | 8 | ||||||||
MIRT484111 | ABCD2 | ATP binding cassette subfamily D member 2 | 2 | 4 | ||||||||
MIRT499834 | PCSK9 | proprotein convertase subtilisin/kexin type 9 | 2 | 8 | ||||||||
MIRT500261 | ZNF788 | zinc finger family member 788 | 2 | 6 | ||||||||
MIRT500551 | XBP1P1 | X-box binding protein 1 pseudogene 1 | 2 | 8 | ||||||||
MIRT502697 | CSNK1G1 | casein kinase 1 gamma 1 | 2 | 4 | ||||||||
MIRT517786 | EFCAB11 | EF-hand calcium binding domain 11 | 2 | 2 | ||||||||
MIRT519191 | IVD | isovaleryl-CoA dehydrogenase | 2 | 2 | ||||||||
MIRT523114 | HSPA4L | heat shock protein family A (Hsp70) member 4 like | 2 | 2 | ||||||||
MIRT527425 | NRL | neural retina leucine zipper | 2 | 2 | ||||||||
MIRT529509 | IYD | iodotyrosine deiodinase | 2 | 2 | ||||||||
MIRT533705 | TMEM67 | transmembrane protein 67 | 2 | 2 | ||||||||
MIRT535694 | NEURL1B | neuralized E3 ubiquitin protein ligase 1B | 2 | 2 | ||||||||
MIRT536141 | MAPK14 | mitogen-activated protein kinase 14 | 2 | 2 | ||||||||
MIRT544878 | ZNF543 | zinc finger protein 543 | 2 | 4 | ||||||||
MIRT551362 | EPM2AIP1 | EPM2A interacting protein 1 | 2 | 2 | ||||||||
MIRT555949 | NUCKS1 | nuclear casein kinase and cyclin dependent kinase substrate 1 | 2 | 2 | ||||||||
MIRT561498 | SRSF2 | serine and arginine rich splicing factor 2 | 2 | 2 | ||||||||
MIRT569681 | AMACR | alpha-methylacyl-CoA racemase | 2 | 2 | ||||||||
MIRT572518 | KIAA0232 | KIAA0232 | 2 | 2 | ||||||||
MIRT572877 | OPHN1 | oligophrenin 1 | 2 | 2 | ||||||||
MIRT572924 | PRAMEF1 | PRAME family member 1 | 2 | 2 | ||||||||
MIRT607528 | ABL2 | ABL proto-oncogene 2, non-receptor tyrosine kinase | 2 | 2 | ||||||||
MIRT611076 | ZNF621 | zinc finger protein 621 | 2 | 2 | ||||||||
MIRT613236 | CCDC39 | coiled-coil domain containing 39 | 2 | 2 | ||||||||
MIRT616542 | NFATC2 | nuclear factor of activated T-cells 2 | 2 | 2 | ||||||||
MIRT620010 | CCDC137 | coiled-coil domain containing 137 | 2 | 2 | ||||||||
MIRT621491 | STYK1 | serine/threonine/tyrosine kinase 1 | 2 | 2 | ||||||||
MIRT622379 | SALL1 | spalt like transcription factor 1 | 2 | 2 | ||||||||
MIRT628226 | FBXL20 | F-box and leucine rich repeat protein 20 | 2 | 2 | ||||||||
MIRT636458 | LRCH3 | leucine rich repeats and calponin homology domain containing 3 | 2 | 2 | ||||||||
MIRT636546 | FAM126B | family with sequence similarity 126 member B | 2 | 2 | ||||||||
MIRT637350 | PIGP | phosphatidylinositol glycan anchor biosynthesis class P | 2 | 2 | ||||||||
MIRT637604 | ZNF554 | zinc finger protein 554 | 2 | 2 | ||||||||
MIRT637732 | EXO5 | exonuclease 5 | 2 | 2 | ||||||||
MIRT638697 | GABRB1 | gamma-aminobutyric acid type A receptor beta1 subunit | 2 | 2 | ||||||||
MIRT640634 | ZIC4 | Zic family member 4 | 2 | 2 | ||||||||
MIRT641535 | SNW1 | SNW domain containing 1 | 2 | 2 | ||||||||
MIRT648796 | VPS8 | VPS8, CORVET complex subunit | 2 | 2 | ||||||||
MIRT663060 | LRIF1 | ligand dependent nuclear receptor interacting factor 1 | 2 | 2 | ||||||||
MIRT666581 | RHOBTB3 | Rho related BTB domain containing 3 | 2 | 2 | ||||||||
MIRT699206 | FYN | FYN proto-oncogene, Src family tyrosine kinase | 2 | 2 | ||||||||
MIRT704875 | CD164 | CD164 molecule | 2 | 2 | ||||||||
MIRT706850 | DNAJB13 | DnaJ heat shock protein family (Hsp40) member B13 | 2 | 2 | ||||||||
MIRT712941 | CCBE1 | collagen and calcium binding EGF domains 1 | 2 | 3 | ||||||||
MIRT714653 | FSTL1 | follistatin like 1 | 2 | 2 | ||||||||
MIRT722320 | SH2D1A | SH2 domain containing 1A | 2 | 2 | ||||||||
MIRT722535 | EPRS | glutamyl-prolyl-tRNA synthetase | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|